Genprex, Inc.

Genprex, Inc. announced a one-for-twenty-two (1:22) reverse stock split of its common stock, effective July 16, 2026. This action will convert every 22 shares into one, with fractional shares rounded up, resulting in an estimated 504,936 shares outstanding post-split from 11,108,577 shares. The company also provided an investor presentation with business updates on its oncology and diabetes gene therapy programs, including ongoing enrollment in Phase 2a of the Acclaim-1 clinical trial.

Genprex announced it received a Notice of Allowance from the Canadian Intellectual Property Office for a patent covering Reqorsa Gene Therapy in combination with PD-1 or PD-L1 antibodies for non-small cell and small cell lung cancer. This expands its intellectual property portfolio, which already includes patents in the U.S., Japan, Europe, and other countries. The patent strengthens protection for therapeutic combinations currently being evaluated in the Acclaim-3 clinical trial. Lung cancer is a leading cause of death in Canada, with 32,900 diagnoses and 19,300 deaths estimated for 2026.

Genprex, Inc. stockholders approved an amendment to the Certificate of Incorporation to effect a reverse stock split, allowing the Board to implement a ratio between one-for-five (1:5) and one-for-fifty (1:50) by December 31, 2027. Additionally, the company's amended and restated 2018 Equity Incentive Plan was approved, increasing the number of shares authorized for issuance by 1,850,000. Stockholders also elected two Class III directors, ratified the appointment of the independent registered public accounting firm, and approved the advisory vote on executive compensation.

Genprex, Inc. received a letter from Nasdaq on June 10, 2026, indicating its common stock is subject to delisting due to non-compliance with the $1.00 minimum bid price requirement over the past 30 consecutive business days. The company is ineligible for a compliance period because it previously effected a reverse stock split on October 21, 2025. Genprex intends to request a hearing before a Nasdaq Hearings Panel, which will automatically stay the delisting action, and plans to take definitive steps, including potentially another reverse stock split, to regain compliance.

Genprex announced the publication of an abstract at the 2026 ASCO Annual Meeting, detailing positive clinical data for its lead drug candidate, Reqorsa® Gene Therapy. The studies identified predictive biomarkers, Trop-2 and PTEN, that correlate with prolonged Progression Free Survival in Non-Small Cell Lung Cancer patients receiving Reqorsa. This clinical validation supports earlier preclinical findings and suggests potential for targeted patient selection and precision medicine.

Genprex, Inc. announced positive preclinical data for its diabetes gene therapy drug candidate, GPX-002 (Pdx1/MafA gene therapy), presented at the 2026 ASGCT Annual Meeting. The data demonstrated that the therapy successfully reversed hyperglycemia in Type 2 diabetic mouse models. Key findings included improved beta-cell function and maturation, with an increase in mature insulin granules, suggesting a fundamental approach to treating T2D. The company believes this preclinical data is a pivotal step towards a potentially transformative treatment offering long-term glycemic control.

Genprex, Inc. reported a net loss of $(4.46) million for the first quarter of 2026, an increase from $(3.96) million in the prior year, though net loss per share improved significantly to $(0.64) due to a higher share count. The company's cash and cash equivalents substantially increased to $18.05 million as of March 31, 2026, driven by $13.36 million in net proceeds from common stock issuances. This financing is expected to fund operations and clinical trials into the second half of 2027, despite ongoing operating losses and a going concern warning. Genprex also provided updates on its Acclaim-1 and Acclaim-3 clinical trials, with interim analyses anticipated in the second half of 2026, and noted the formation of Convergen Biotech, Inc. for a potential diabetes program separation.

Genprex, Inc. announced that the Israel Patent Office has granted a patent for Reqorsa® Gene Therapy (quaratusugene ozeplasmid) for use in combination with PD-1 antibodies for cancer treatment. This strategic expansion builds upon the company's existing intellectual property in numerous major markets worldwide. Reqorsa is initially being developed for lung cancer, a significant health concern in Israel, where lung cancer cases increased by 33% within a decade by 2020 and was the leading cause of cancer death in 2021.

Genprex, Inc. will hold its 2026 Annual Meeting of Stockholders virtually on June 18, 2026. Stockholders will vote on several key proposals, including the election of two Class III directors, the ratification of WithumSmith+Brown, PC as the independent auditor, and an advisory vote on executive compensation. A significant proposal includes the approval of an amendment to the Company's Certificate of Incorporation to effect a reverse stock split at a ratio between 1:5 and 1:50, at the Board's discretion, before December 31, 2027. Additionally, stockholders will vote on approving an amended and restated 2018 Equity Incentive Plan.

Genprex, Inc. announced that its research collaborators will present positive preclinical data for its diabetes gene therapy drug candidate, GPX-002 (Pdx1/MafA gene therapy), at the 2026 ASGCT Annual Meeting. The data demonstrated that GPX-002 reversed hyperglycemia in Type 2 diabetic mouse models, significantly improving β-cell function and maturation. The findings suggest the technical translatability of this approach to human application for long-term glycemic control.